Position:
Clinical Professor
Division:
Nephrology
Education:
B.Sc. McGill University
MDCM McGill University
Recent Publications:
  • Fung M, Thompson D, Shapiro RJ, Warnock GL, Andersen DK, Elahi D, Meneilly GS.  Effect of glucagon-like peptide-1 (7-37) on beta cell function after islet transplantation in type 1 diabetes.  Diabetes Res Clin Pract 2006: 74 (2): 189-93.
  • Dmitrienko S, Yu A, Balshaw R, Shapiro RJ, Keown PA.  The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation.  Kidney Int. 2007: 72 (8); 1014-22.
  • Fung MA, Warnock GL, Ao Z, Keown P, Meloche M, Shapiro RJ, Ho S, Worsley D, Meneilly GS, Ghofaili KA, Kozak SE, Tong SO, Trinh, M, Blackburn L, Kozak RM, Fensom BA, Thompson DM.  The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report.  Transplantation 2007: 84: 17-22.
  • Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS, Thompson DM.  Effect of exenatide on beta cell function after islet transplantation in type I diabetes.  Transplantation 2007: 83 (1): 24-28.
  • Rush D, Arlen D, Boucher A, Busque S, Cockfield S, Girardin C, Knoll G, Lachance JG, Landsberg D, Shapiro J, Shoker A, Yilmaz S.  Lack of benefit of early protocol biopsies in renal transplant patients receiving FK506 and MMF: a randomized study. Am J Transplantation 2007: 7: 2538-45.
  • Thornton WJL, Deria S, Gelb S, Shapiro RJ, Hill A.  Neuropsychological mediators of the links among age, chronic illness, and everyday problem solving.  Psychol Aging 2007: 22 (3): 470-481.
  • Thornton WJL, Shapiro RJ, Deria S, Gelb S, Hill A.  Differential impact of age on verbal memory and executive functioning in chronic kidney disease.  J Int Neuropsychol Soc 2007: 13 (2): 344-53.
  • Dmitrienko S, Yu A, Balshaw R, Shapiro RJ, Keown PA.  The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation.  Kidney Int. 2007: 72 (8); 1014-22.
  • Gelb S, Shapiro RJ, Hill A, Thornton WL.  Cognitive outcome following kidney transplantation.  Nephrol Dial Transplant 2008: 23 (3) 1032-8.
  • Jevnikar A, Arlen D, Barrett B, Boucher A, Cardella C, Cockfield SM, Rush D, Paraskevas S, Shapiro J, Shoker A, Yilmaz S, Zaltzman JS, Kiberd B.  Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.  Transplantation 2008; 86 (7); 953-60.
  • Thompson DM, Begg IA, Harris C, Ao Z, Fung MA, Meloche RM, Keown P, Meneilly GS, Shapiro RJ, Ho S, Dawson KG, Al Ghofaili K, Al Riyami L, Al Mehthel M, Kozak SE, Tong SO, and Warnock GL.  Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy.  Transplantation 2008: 85 (10); 1400-1405.
  • Warnock GL, Thompson DM, Meloche RM, Shapiro RJ, Ao Z, Keown P, Johnson J, Verchere CB, Partovi N, Begg IS, Fung M, Kozak SE, Tong SO, Alghofaili KM, Harris C.  A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes.  Transplantation 2008; 86 (12); 1762-1766.
  • Barraclough KA, Landsberg DN, Shapiro RJ, Gill JS, Li G, Balshaw RF, Chailimpamontree W, Keown PA, for the Genome Canada Biomarkers in Transplantation Group.  A matched cohort pharmacoepidemiological analysis of steroid free immunosuppression in renal transplantation. Transplantation 2009; 87 (5); 672-80.
  • Chailimpamontree W, Dmitrienko S, Li G, Balshaw RF, Mahil A, Shapiro RJ, Landsberg DN, Gill J, Keown PA, and the Genome Canada Biomarkers in Transplantation Group.  Probability, predictors, and prognosis of post-transplant glomerulonephritis.  J Am Soc Neph 2009; 20 (4); 843-51.
  • Dmitrienko S, Balshaw R, Machnicki G, Shapiro RJ, Keown PA.  Probabilistic modeling of CMV infection under consensus clinical management guidelines.  Transplantation 2009; 87 (4); 570-.
  • Rush DN, Cockfield SM, Nickerson PW, Arlen DJ, Boucher A, Busque S, Girardin CE, Knoll GA, Lachance JG, Landsberg DN, Shapiro RJ, Shoker A, Yilmaz S.  Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolatemofetil.  Transplantation 2009; 88 (7); 897-903.
  • Al-Khatib M, Shapiro RJ, Partovi N, Ting LS, Ensom MH. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients.  Ther Drug Monit 2010; 32 (3); 373-378.
  • Al-Khatib M, Shapiro RJ, Partovi N, Ting LSL, Levine M, Ensom MHH. Limited sampling strategies for predicting area under the concentration-time curve of mycophenolic acid in islet transplant recipients.  Ann Pharmacother 2010; 44 (1); 19-27.
  • Gelb SR, Shapiro RJ, Thornton WJL.  Predicting medication adherence and employment status following kidney transplantation: the relative utility of traditional and everyday cognitive approaches.  Neuropsychology, 2010: 24 (4); 514-526.
  • Gill JS, Landsberg D, Johnston O, Shapiro RJ, Magil A, Wu V, Tinckam K, Keown P.  Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection.  Transplantation 2010; 89 (2); 178-184.
  • Haque M, Webber DL, Kebarle P, Shapiro RJ, Yoshida EM.  Hepatic lymphoma in a post renal transplant patient with chronic hepatitis B.  Ann Hepatol 2010; 9 (1); 91-92.
  • Keough-Ryan TM, Prasad GVR, Hewlett T, Shapiro RJ.  Similar outcomes for Canadian renal transplant recipients followed in transplant centers and satellite clinics.  Transplantation 2010: 90 (6); 591-596.
  • Landsberg DN, Shapiro RJ.  Kidney, Pancreas, and Pancreatic Islet Transplantation.  BC Medical Journal 2010; 52 (4); 189-196.
  • Prasad GVR, Nash MM, Keough-Ryan T, Shapiro RJ.  A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients followed across Canada.  J Nephrology 2010: 23 (3); 274-281.
  • Poulin E, Greanya ED, Partovi N, Shapiro RJ, Al-Khatib M, Ensom MH. Development and validation of limited sampling strategies for tacrolimus and mycophenolate in steroid-free renal transplant regimens.  Ther Drug Monit 2011; 33 (1): 50-5.
  • Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ, Ho S, Worsley D, Fung M, Meneilly G, Begg I, Al Mehthel M, Kondi J, Harris C, Fensom B, Kozak SE, Tong SO, Trinh M, Warnock GL.   Reduced progression  of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy.  Transplantation 2011: 91 (3); 373-378.